245 related articles for article (PubMed ID: 28643680)
1. [Towards precision medicine in myeloma: new evidence and challenges].
González-Calle V; Fonseca R
Medicina (B Aires); 2017; 77(3):222-226. PubMed ID: 28643680
[TBL] [Abstract][Full Text] [Related]
2. Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach.
González-Calle V; Keane N; Braggio E; Fonseca R
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):621-630. PubMed ID: 28743429
[TBL] [Abstract][Full Text] [Related]
3. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.
Harding T; Baughn L; Kumar S; Van Ness B
Leukemia; 2019 Apr; 33(4):863-883. PubMed ID: 30683909
[TBL] [Abstract][Full Text] [Related]
4. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
Mitsiades CS; Davies FE; Laubach JP; Joshua D; San Miguel J; Anderson KC; Richardson PG
J Clin Oncol; 2011 May; 29(14):1916-23. PubMed ID: 21482978
[TBL] [Abstract][Full Text] [Related]
5. Toward personalized treatment in multiple myeloma based on molecular characteristics.
Pawlyn C; Davies FE
Blood; 2019 Feb; 133(7):660-675. PubMed ID: 30587529
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Voorhees PM; Jakubowiak AJ; Kumar SK; Kanapuru B; Baines AC; Bhatnagar V; Ershler R; Theoret MR; Gormley NJ; Pazdur R
Clin Cancer Res; 2022 Jan; 28(1):23-26. PubMed ID: 34315721
[TBL] [Abstract][Full Text] [Related]
7. Clinical target sequencing for precision medicine of breast cancer.
Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
[TBL] [Abstract][Full Text] [Related]
8. Utilizing next-generation sequencing in the management of multiple myeloma.
Lionetti M; Neri A
Expert Rev Mol Diagn; 2017 Jul; 17(7):653-663. PubMed ID: 28524737
[TBL] [Abstract][Full Text] [Related]
9. Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.
Mogollón P; Díaz-Tejedor A; Algarín EM; Paíno T; Garayoa M; Ocio EM
Cells; 2019 Nov; 8(11):. PubMed ID: 31766279
[TBL] [Abstract][Full Text] [Related]
10. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
11. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
12. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
13. Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?
Lourenço D; Lopes R; Pestana C; Queirós AC; João C; Carneiro EA
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361677
[TBL] [Abstract][Full Text] [Related]
14. Cancer genomics guide clinical practice in personalized medicine.
Lehmann-Che J; Poirot B; Boyer JC; Evrard A
Therapie; 2017 Sep; 72(4):439-451. PubMed ID: 28258721
[TBL] [Abstract][Full Text] [Related]
15. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
16. Genomic heterogeneity in multiple myeloma.
Szalat R; Munshi NC
Curr Opin Genet Dev; 2015 Feb; 30():56-65. PubMed ID: 25982873
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance in Multiple Myeloma.
Papadas A; Asimakopoulos F
Handb Exp Pharmacol; 2018; 249():251-288. PubMed ID: 28315070
[TBL] [Abstract][Full Text] [Related]
18. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Collins DC; Sundar R; Lim JSJ; Yap TA
Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
[TBL] [Abstract][Full Text] [Related]
19. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
20. Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?
Chung C; Ma H
Pharmacotherapy; 2017 Sep; 37(9):1052-1072. PubMed ID: 28654205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
